Beacon Energy plc, intends to join the AIM market. In accordance with the Company's strategy to focus on growth through acquisition or farm-in to oil and gas projects, the Company entered into the SPA with Tulip Oil Holdings B.V. In conjunction with the Acquisition, the Company has conditionally raised total gross proceeds of £6.04m and will be used to fund the drilling of the SCHB-2 development well onshore Germany and for working capital. Expected admission date is 11 April 2023.
Ocean Harvest Technology Group plc, a commercial scale producers of seaweed blend ingredients for the animal feed market intends to join AIM. The main country of operation is Vietnam where the Company's main production and processing facility is located. The Company is headquartered in Theale, UK with further operations in Galway, Ireland and Binh Duong Province, Vietnam. Expected Admission was on 29th March 2023 (appears delayed).
M7 Box+ REIT plc, a newly established, externally managed closed-ended investment company announces that it intends to join the Wholesale segment of IPSX. Upon Admission, the Company proposes to acquire a portfolio of seven let and operational e-warehouses from M7 Box+ II LP. As at 31 December 2022, the Property Portfolio was valued at £228.9m. Expected Admission April 2023.
Fadel Partners, a developer of cloud based brand compliance and rights and royalty management software, working with some of the world's leading licensors and licensees across media, entertainment, publishing, consumer brands and hi-tech & gaming companies intends to join the AIM market. FADEL has two solutions, being IPM Suite and Brand Vision. Expected capital raise on Admission of £7.5m and Market Capitalisation of £28.8m. Expected Admission 6 April 2023.
Aquis Exchange 395p £108.7m (AQX.L)
The creator and facilitator of next-generation financial markets announces the launch of Aquis Equinox: a world-first, regulated market-grade 24x7 matching engine which never requires shut down or downtime. Traditional exchange models require downtime at set periods to ensure required actions including maintenance and software upgrades are implemented. Exchanges running on Aquis Equinox can guarantee continuous operation, with no need for shutdown. Aquis Equinox combines this uninterrupted availability with high regulatory standards, alongside extreme fault tolerance and proprietary engineering.
D4t4 Solutions 180p £71.7m (D4T4.L)
The data solutions provider provides the following trading update for the year to 31 March 2023. Due to the delays in the signing of a project with an existing customer ,which included a high proportion of low margin hardware, and a Celebrus multi-year contract with a new customer, results are expected to be lower than management expectations, with full year revenues in the region of approximately £21.5m (FY22: £24.5m) and adjusted profit before tax of c.£3.5m (FY22: £3.3m). The cash balance was £17.7m at 31 March 2023 (FY22: £11.4m), with no debt. The Group will continue to invest in sales and marketing for the core business to build upon the growth.
Elixirr International 505p £233.2m (ELIX.L)
An established, global award-winning challenger consultancy announces its final results for the year ended 31 December 2022. Revenue increased by 40% to £70.7m (FY 21: £50.6m), adjusted EBITDA increased by 30% to £20.5m (FY 21: £15.7m), profit before tax increased by 29% to £15.7m (FY 21: £12.2m) and the Company holds net cash of £20.4m (FY 21: £31.8m). FY 22 momentum has continued during Q1 2023, with absolute revenue growth of 52%. FY 23 expectations upgraded to £85m-£90m revenue at an adjusted EBITDA margin of 28-30%.
EnSilica 73.5p £57.4m (ENSI.L)
A leading mixed signal chip maker announces that it has secured a contract with an existing European based customer for approximately $2.4m (Contract). The third Contract secured by EnSilica with this customer, is to develop a TSMC 12nm FinFET ASIC using multiple high-speed Ethernet network interfaces. The Contract revenue spans the current and next financial year of the Company. This most recent award follows a period of strong new business momentum with contracts announced totalling c.$13.5m and underpinning current market expectations.
Judges Scientific £85.80 £546.7m (JDG.L)
A group focused on acquiring and developing companies in the scientific instrument sector announces that it has acquired 100% of the issued share capital of Henniker Scientific Limited. A company specialising in deposition and plasma technology based in Runcorn, Cheshire. The initial consideration for Henniker is £1.8m in cash plus an earn-out payment due in 2024 and equal to four times EBIT for the year ended 31 March 2024, minus £1.8m. The consideration for the acquisition has been funded from the Group's cash balances. The Board believes that Henniker is a solid, growing and profitable company manufacturing quality products.
MyHealthChecked 0.97p £7.6m (MHC.L)
The consumer home-testing healthcare company announces its preliminary results for the year ended 31 December 2022. Revenue up 36% to £22.3m (2021: £16.4m), adjusted EBITDA of £2.3m (2021: £2.7m) - reflecting the change in product mix away from higher margin PCR testing to the distribution of COVID Lateral Flows, and cash balance at year end of £7.6m (2021: £6.4m). The Company is developing B2B2C customer relationships in preparation to launch an expanded portfolio of at-home wellness tests nationwide in 2023. The Company aims to continue to solidify its position as a leading wellness company.
NetScientific 70p £16.4m (NSCI.L)
The investment and commercialisation group with an international portfolio of innovative life science, sustainability and industrial technology companies provides a business update for the year ended 31 December 2022. The Group expects an increase in Fair Value. H2 2022 saw a marked increase in activity, with companies achieving significant operational milestones and key fundraisings across the Group's portfolio, an aggregate amount of c.£70m was raised through equity and venture debt by 18 companies. The Group introduced three new investments into the portfolio and the Board is optimistic about the potential for enhanced value creation and potential liquidity events.
Sirius Real Estate 77.25p £908.4m (SRE.L)
The leading owner and operator of branded business and industrial parks providing conventional space and flexible workspace in Germany and the U.K. announces that it has completed the disposals of two assets for a combined total of EUR12.2m. The most recent disposal, which completed on 1 April 2023, was achieved at a 5.3% premium to book value (30 September 2022: EUR8.3m) originally acquired by Sirius in 2007 and sold for EUR8.8m. This disposal follows the EUR3.4m sale at book value (as at 30 September 2022) which completed in December 2022. The Company aims to use the returns investing into new opportunities within its portfolio where it sees an opportunity to create value.
Strip Tinning Holdings 52.5p £8.1m (STG.L)
A leading supplier of specialist connectors to the automotive sector announces that it has secured a new order for a large number of sample cell contact system modules from the Company's leading EV customer, supplying into the autonomous vehicle industry in the USA. The value of the order is c.£775k, with the majority of the parts expected to be shipped in 2023 and the Company anticipates next receiving C-sample orders as a result. This order renews the confidence in the Company for their commercial opportunity in the EV sector.
Tracsis 890p £266.0m (TRCS.L)
A leading provider of software, hardware, data analytics/ GIS and services for the rail, traffic data and wider transport industries announces its unaudited interim results for the six months ended 31 January 2023. 34% increase in revenue to £39.2m (H1 2022: £29.2m), adjusted EBITDA increased by 21% to £7.5m (H1 2022: £6.2m), 76% increase in profit before tax to £2.3m (H1 2022: £1.3m) and the Company holds cash balances of £17.0m with no debt. The Company has seen further growth in rail technology software licence usage and annual recurring revenue and the Board's expectations for the year to 31 July 2023 remain unchanged.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
